Platelet Aggregation Inhibitors
Tech ID: 18905 / UC Case 2001-089-0
Thrombin is an enzyme in the blood that plays a key role in platelet formation during injury. While blood coagulation is essential for a surface wound, platelet activation underlies various pathological situations such as unstable angina pectoris, myocardial infarction and stroke. Thrombin is mediated by protease activated receptor-1 (PAR-1) which is expressed in the nervous system and in platelets. Once activated by thrombin, PAR-1 induces rapid and dramatic changes in cell morphology that is controlled by a series of localized ATP-dependent reactions.
Researchers at the University of California have discovered specific creatine kinase inhibitors that inhibit thrombin-induced aggregation of platelets. These creatine kinase inhibitors could be used to treat a disease or disorder that is caused by pathological platelet aggregation.
This treatment has applications both for humans and in veterinary medicine.
|United States Of America||Issued Patent||6,444,695||09/03/2002||2001-089|
PEOPLE WHO VIEWED THIS ALSO VIEWED THESE TECHNOLOGIES BY OTHER INVENTORS
- ADP Glucose Receptor as a Target for Disorders Involving Platelet Aggregation
- New Chemical Entities for the Treatment and Prevention of Diabetes and Metabolic Disorders
- Transgenic Mouse Model for Screening Analgesic Agents
- Neuropeptide S (NPS) as a Treatment for Anxiety, Sleep Disorders, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, and Asthma
- Melanin Concentrating Hormone Receptor Small Molecule Antagonists for the Treatment of Obesity and Related Metabolic Disorders